Rapport Therapeutics announced public offerings of $200 million in common stock and $150 million in convertible senior notes, with options for additional shares and notes. The company plans to use the proceeds to fund clinical trials for its lead drug RAP-219, research and development, and general corporate purposes. A concurrent private placement with a separate investor is also planned. These offerings are subject to market conditions and aim to support Rapport's precision neuroscience pipeline targeting neurological and psychiatric disorders.
Rapport Therapeutics' proposed public offerings provide context for the health sector's market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 28, 2026 03:11 WIB: Out of 150 priced US health-sector stocks, 88 rose and 62 fell. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 11.21 with a 1-day change of +11.93%, BFLY (Butterfly Network Inc. Class A Common Stock) at USD 7.38 with +10.81%, and IBRX (ImmunityBio Inc. Common Stock) at USD 8.61 with +10.24%.
Vallourec will publish its Q3 2026 financial results on November 20, 2026, at 07:30 AM CET. The company's CEO Philippe Guillemot and CFO Nathalie Delbreuve will present the results via a conference call and webcast at 09:30 AM CET the same day. Inves...
MyPropCapital Technology Limited has launched a new trading evaluation platform that uses the Arbitrum One blockchain to record all fees, rules, passes, and rewards publicly. This system allows traders to verify every detail of their trading deals wi...
The European Central Bank (ECB) has confirmed KBC Group's minimum capital requirements for 2026 following its Supervisory Review and Evaluation Process (SREP). KBC must maintain a fully loaded CET1 ratio of 10.94%, which includes various regulatory b...
Bitget Wallet introduced Virtual Account, allowing users to open free USD and EUR accounts within their self-custodial crypto wallet, powered by licensed partner Noah. Funds deposited convert automatically to stablecoins like USDT or USDC, usable for...
The European Central Bank (ECB) has confirmed KBC Group's minimum capital requirements for 2026, maintaining the Pillar 2 Requirement at 1.95% and Pillar 2 Guidance at 1.00%. This results in an overall CET1 capital requirement of 10.94%. As of Q2 202...
